

AD_____

Award Number: W81XWH-04-1-0314

TITLE: Prostate Cancer Aggressiveness Genes in Hereditary
Prostate Cancer

PRINCIPAL INVESTIGATOR: Kathleen A. Cooney, M.D.

CONTRACTING ORGANIZATION: The University of Michigan Medical School
Ann Arbor, Michigan 48109-0602

REPORT DATE: March 2005

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20060503129

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY
(Leave blank)**2. REPORT DATE**
March 2005**3. REPORT TYPE AND DATES COVERED**
Annual (1 Mar 2004 - 28 Feb 2005)**4. TITLE AND SUBTITLE**

Prostate Cancer Aggressiveness Genes in Hereditary Prostate Cancer

5. FUNDING NUMBERS

W81XWH-04-1-0314

6. AUTHOR(S)

Kathleen A. Cooney, M.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)The University of Michigan Medical School
Ann Arbor, Michigan 48109-0602**8. PERFORMING ORGANIZATION
REPORT NUMBER****E-Mail:** kcooney@umich.edu**9. SPONSORING / MONITORING
AGENCY NAME(S) AND ADDRESS(ES)**U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012**10. SPONSORING / MONITORING
AGENCY REPORT NUMBER****11. SUPPLEMENTARY NOTES****12a. DISTRIBUTION / AVAILABILITY STATEMENT**

Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE**13. ABSTRACT (Maximum 200 Words)**

No abstract provided.

14. SUBJECT TERMS

No subject terms provided.

15. NUMBER OF PAGES

5

16. PRICE CODE**17. SECURITY CLASSIFICATION
OF REPORT**

Unclassified

**18. SECURITY CLASSIFICATION
OF THIS PAGE**

Unclassified

**19. SECURITY CLASSIFICATION
OF ABSTRACT**

Unclassified

20. LIMITATION OF ABSTRACT

Unlimited

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusions.....	5

INTRODUCTION: The *EZH2* transcriptional regulator, recently shown by to be overexpressed in prostate cancer specimens that are more likely to recur, maps to 7q35 and represents a candidate gene for inherited prostate cancer susceptibility. This statement is based on the identification of prostate cancer linkage to distal 7q markers in a recently completed genome-wide scan using hereditary prostate cancer families from the University of Michigan Prostate Cancer Genetics Project (PCGP). Relatively little is known about the molecular basis of *EZH2* function or its DNA specificity. The major hypothesis of this proposal is that germline mutations in the *EZH2* gene will predispose to more clinically aggressive forms of prostate cancer and the characterization of these mutations will provide more information about the function of the *EZH2* molecule in prostate cancer and metastasis. To address this hypothesis, the following two specific aims were proposed: 1) to identify germline mutations in *EZH2* that predispose to aggressive prostate cancer in prostate cancer families, and 2) to characterize the functional consequences of *EZH2* mutations specifically focusing on the role of *EZH2* in transcriptional regulation.

BODY: To address Specific Aim 1, we have revised our current IRBMED approved research project to add this DOD-funded research project. The revised proposal is under review by our University of Michigan IRB. We expect that this will be approved by April 2005. In the interim, we have designed sequencing primers to span all of the *EZH2* coding regions. The primers have been tested on control DNA samples and conditions for amplification have been standardized.

To address Specific Aim 2, we have modified a molecular biological technique first developed in yeast, known as the TAP (tandem affinity purification) system, which has allowed us to express a tagged form of *EZH2* in human cells at physiological concentrations, and subsequently to purify *EZH2*-associated proteins from cells. We have identified several *EZH2*-binding proteins by mass spectrometry, and our lead candidate is a recently described factor designated REA (repressor of estrogen activity). We have isolated full-length cDNA clones encoding REA, and generated a range of mammalian expression vectors, both with and without epitope tags. Through coprecipitation experiments, we have confirmed the validity of the interaction, and our studies have now moved to the next phase, namely the functional characterization of the two proteins to determine the physiological consequences of the interaction.

REA has been shown to bind directly to the estrogen receptor (ER), and can function to suppress ER-mediated activity. We therefore are taking several approaches to examine the functional consequences of the *EZH2*-REA interaction. Firstly, we have established a system described recently by the laboratory of Danny Reinberg, in which the transcription suppressing activity of *EZH2* is examined through the use of a Gal4-*EZH2* chimera. By monitoring the expression of a Gal4-dependent luciferase reporter construct, we are in the process of examining the effects of either ectopic expression, or removal by RNA interference, of REA on *EZH2* activity.

We have obtained several monoclonal antibodies specific to REA, and we are taking an immunohistochemical approach to examine a panel of histological samples to determine whether REA expression is altered in prostate cancer.

Finally, we are testing the reciprocal possibility, namely that *EZH2* is involved in REA function, and to this end we have established a similar luciferase-based reporter

system to that described above to examine the effect of *EZH2* on estrogen receptor-mediated transcription. The hypothesis being tested is that REA-mediated inhibition of ER activity may be modulated by, or even mediated by *EZH2*.

KEY RESEARCH ACCOMPLISHMENTS:

Specific Aim 1	Completion and approval of IRB protocols. Design and validation of exon-specific primers
Specific Aim 2	Establishment of <i>EZH2</i> -TAP system Purification and identification of <i>EZH2</i> -associated proteins Validation of REA as a physiologically relevant <i>EZH2</i> -associated protein Characterization of REA-specific antibodies for Immunohistochemistry Establishment of reporter systems to analyze <i>EZH2</i> and REA Activity Design and validation of small interfering RNAs (siRNAs) for REA and XIAP

REPORTABLE OUTCOMES: None to date.

CONCLUSIONS: We are now very excited about the ability to proceed with Specific Aim 1, having, we believe, updated and amended the IRB protocols in a manner which is satisfactory to the DOD. Specific Aim 2 has also seen significant progress, with the identification and validation of REA as a previously undescribed *EZH2*-interacting protein. In summary, we feel that we are well underway in the successful undertaking of our aims.